OBJECTIVES: The World Health Organization convened a panel of experts to rank the evidence for medical countermeasures for management of acute radiation syndrome (ARS) in a hypothetical scenario involving the hospitalization of 100 to 200 victims. The goal of this panel was to achieve consensus on optimal management of ARS affecting nonhematopoietic organ systems based upon evidence in the published literature. METHODS: English-language articles were identified in MEDLINE and PubMed. Reference lists of retrieved articles were distributed to conferees in advance of and updated during the meeting. Published case series and case reports of ARS, publications of randomized controlled trials of relevant interventions used to treat nonirradiated individuals, reports of studies in irradiated animals, and prior recommendations of subject matter experts were selected. Studies were extracted using the Grading of Recommendations Assessment Development and Evaluation system. In cases in which data were limited or incomplete, a narrative review of the observations was made. RESULTS: No randomized controlled trials of medical countermeasures have been completed for individuals with ARS. Reports of countermeasures were often incompletely described, making it necessary to rely on data generated in nonirradiated humans and in experimental animals. A strong recommendation is made for the administration of a serotonin-receptor antagonist prophylactically when the suspected exposure is >2 Gy and topical steroids, antibiotics, and antihistamines for radiation burns, ulcers, or blisters; excision and grafting of radiation ulcers or necrosis with intractable pain; provision of supportive care to individuals with neurovascular syndrome; and administration of electrolyte replacement therapy and sedatives to individuals with significant burns, hypovolemia, and/or shock. A strong recommendation is made against the use of systemic steroids in the absence of a specific indication. A weak recommendation is made for the use of fluoroquinolones, bowel decontamination, loperamide, and enteral nutrition, and for selective oropharyngeal/digestive decontamination, blood glucose maintenance, and stress ulcer prophylaxis in critically ill patients. CONCLUSIONS: High-quality studies of therapeutic interventions in humans exposed to nontherapeutic radiation are not available, and because of ethical concerns regarding the conduct of controlled studies in humans, such studies are unlikely to emerge in the near future.
OBJECTIVES: The World Health Organization convened a panel of experts to rank the evidence for medical countermeasures for management of acute radiation syndrome (ARS) in a hypothetical scenario involving the hospitalization of 100 to 200 victims. The goal of this panel was to achieve consensus on optimal management of ARS affecting nonhematopoietic organ systems based upon evidence in the published literature. METHODS: English-language articles were identified in MEDLINE and PubMed. Reference lists of retrieved articles were distributed to conferees in advance of and updated during the meeting. Published case series and case reports of ARS, publications of randomized controlled trials of relevant interventions used to treat nonirradiated individuals, reports of studies in irradiated animals, and prior recommendations of subject matter experts were selected. Studies were extracted using the Grading of Recommendations Assessment Development and Evaluation system. In cases in which data were limited or incomplete, a narrative review of the observations was made. RESULTS: No randomized controlled trials of medical countermeasures have been completed for individuals with ARS. Reports of countermeasures were often incompletely described, making it necessary to rely on data generated in nonirradiated humans and in experimental animals. A strong recommendation is made for the administration of a serotonin-receptor antagonist prophylactically when the suspected exposure is >2 Gy and topical steroids, antibiotics, and antihistamines for radiation burns, ulcers, or blisters; excision and grafting of radiationulcers or necrosis with intractable pain; provision of supportive care to individuals with neurovascular syndrome; and administration of electrolyte replacement therapy and sedatives to individuals with significant burns, hypovolemia, and/or shock. A strong recommendation is made against the use of systemic steroids in the absence of a specific indication. A weak recommendation is made for the use of fluoroquinolones, bowel decontamination, loperamide, and enteral nutrition, and for selective oropharyngeal/digestive decontamination, blood glucose maintenance, and stress ulcer prophylaxis in critically illpatients. CONCLUSIONS: High-quality studies of therapeutic interventions in humans exposed to nontherapeutic radiation are not available, and because of ethical concerns regarding the conduct of controlled studies in humans, such studies are unlikely to emerge in the near future.
Authors: Tener Goodwin Veenema; Bonnie Walden; Nancy Feinstein; Jacqueline P Williams Journal: Disaster Med Public Health Prep Date: 2008-12 Impact factor: 1.385
Authors: Simon Finfer; Dean R Chittock; Steve Yu-Shuo Su; Deborah Blair; Denise Foster; Vinay Dhingra; Rinaldo Bellomo; Deborah Cook; Peter Dodek; William R Henderson; Paul C Hébert; Stephane Heritier; Daren K Heyland; Colin McArthur; Ellen McDonald; Imogen Mitchell; John A Myburgh; Robyn Norton; Julie Potter; Bruce G Robinson; Juan J Ronco Journal: N Engl J Med Date: 2009-03-24 Impact factor: 91.245
Authors: C Norman Coleman; Chad Hrdina; Judith L Bader; Ann Norwood; Robert Hayhurst; Joseph Forsha; Kevin Yeskey; Ann Knebel Journal: Ann Emerg Med Date: 2008-04-03 Impact factor: 5.721
Authors: A M G A de Smet; J A J W Kluytmans; B S Cooper; E M Mascini; R F J Benus; T S van der Werf; J G van der Hoeven; P Pickkers; D Bogaers-Hofman; N J M van der Meer; A T Bernards; E J Kuijper; J C A Joore; M A Leverstein-van Hall; A J G H Bindels; A R Jansz; R M J Wesselink; B M de Jongh; P J W Dennesen; G J van Asselt; L F te Velde; I H M E Frenay; K Kaasjager; F H Bosch; M van Iterson; S F T Thijsen; G H Kluge; W Pauw; J W de Vries; J A Kaan; J P Arends; L P H J Aarts; P D J Sturm; H I J Harinck; A Voss; E V Uijtendaal; H E M Blok; E S Thieme Groen; M E Pouw; C J Kalkman; M J M Bonten Journal: N Engl J Med Date: 2009-01-01 Impact factor: 91.245
Authors: C Norman Coleman; Julie M Sullivan; Judith L Bader; Paula Murrain-Hill; John F Koerner; Andrew L Garrett; David M Weinstock; Cullen Case; Chad Hrdina; Steven A Adams; Robert C Whitcomb; Ellie Graeden; Robert Shankman; Timothy Lant; Bert W Maidment; Richard C Hatchett Journal: Health Phys Date: 2015-02 Impact factor: 1.316
Authors: Ann M Farese; Melanie V Cohen; Barry P Katz; Cassandra P Smith; Allison Gibbs; Daniel M Cohen; Thomas J MacVittie Journal: Radiat Res Date: 2012-12-04 Impact factor: 2.841
Authors: Andrea L DiCarlo; Aaron C Bandremer; Brynn A Hollingsworth; Suhail Kasim; Adebayo Laniyonu; Nushin F Todd; Sue-Jane Wang; Ellen R Wertheimer; Carmen I Rios Journal: Radiat Res Date: 2020-09-16 Impact factor: 2.841